Variants of concern of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have shown the ability to avoid vaccine-induced and natural immunity. The Delta variant is now responsible for over 90% of new cases. In a study published in the New…

A study in the Philadelphia area found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants evolve to become more contagious and resistant to COVID-19 vaccines. In addition, depending on the sublineage, SARS-CoV-2 variants such as the Delta variant led…

The messenger RNA (mRNA) COVID-19 vaccines are relatively safe, with the majority of self-reported side-effects being mild and short in duration, according to findings from scientists at the U.S. Food & Drug Administration and the Centers for Disease Control and…

The coronavirus disease 2019 (COVID-19) pandemic has heightened many social and economic disparities, in addition to the biological risk factors that have put several ethnicities at greater risk of hospitalization and death due to severe COVID-19. Vaccination appears to be…

The concentration of the proteins S100A8 and S100A9 in serum increases during an inflammatory response. Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) show elevated serum levels of S100A8 and S100A9. Additionally, the S100A8/A9 complex is considered a…

A recent review describes the role of nanobodies as a new class of recombinant antibodies that are used in the treatment of the coronavirus disease 2019 (COVID-19). Study: The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization. Image Credit:…

The coronavirus disease 2019 (COVID-19) pandemic caused many countries to enact costly restrictions on freedom of movement and business. The rapid transmission of the disease and high mortality amongst at-risk groups such as the immunocompromised lead to the disease-causing over…

The currently available coronavirus disease 2019 (COVID-19) vaccines have markedly reduced the burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) where available. Still, the global disparity in availability and concerns regarding the emergence of vaccine-evading mutants continue to encourage…

The coronavirus disease 2019 (COVID-19) pandemic has resulted in an intense focus on the development of vaccines. Animal models have been utilized to evaluate the efficacy of newly developed vaccines and to define molecular and immunologic correlates of protection. Study:…

Is one COVID vaccine better than the other? Four current vaccines — Moderna, Pfizer-BioNTech, Johnson & Johnson, and AstraZeneca — are highly effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but a new medRxiv* study suggests the level of…